{"id":2907,"date":"2026-09-02T00:00:00","date_gmt":"2026-09-02T04:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2907"},"modified":"2026-09-04T16:53:54","modified_gmt":"2026-09-04T20:53:54","slug":"engineered-attachment-sites-raise-bxb1-integration","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2907","title":{"rendered":"Engineered Attachment Sites Raise Bxb1 Integration"},"content":{"rendered":"

Institution:<\/strong> Qi Biodesign · Method:<\/strong> Engineered attB Attachment Sites (Bxb1 Integrase) · Cargo Demonstrated:<\/strong> CD19-CAR (31%) + OTC Cassette (25%) · Study Type:<\/strong> Peer-Reviewed (Nature Biotechnology) · Date:<\/strong> September 2, 2026<\/p>\n

\"Engineered<\/p>\n

Summary<\/h4>\n

Qi Biodesign researchers rationally engineered Bxb1 attachment-site DNA rather than only the integrase protein, identifying attB(V111) and related variants that increased large-cargo integration in human cells and plants. Combining engineered DNA and protein produced 31% CD19-CAR and 25% OTC-cassette insertion in HEK293T cells. The work expands programmable gene-insertion design space but remains cell-line and plant evidence without therapeutic delivery or in-vivo safety.<\/p>\n

What Happened<\/h4>\n

The team assembled 144 chimeric attB sequences from natural Bxb1-recognition motifs. attB(V111) achieved 51.9% integration in HEK293T cells, 1.7-fold above wild type, and 35.6% in rice protoplasts, 4.4-fold above wild type. The method uses prime editing to install a genomic landing site followed by integrase-mediated donor insertion. Pairing an optimized attachment site with an engineered Bxb1 catalytic-domain variant produced targeted insertion of a CD19 CAR cassette at 31% and an ornithine-transcarbamylase cassette at 25% in human cells. The reported human experiments used HEK293T cells, not primary T cells, hepatocytes, HSPCs or disease models. In rice, a 5.8-kb cassette was stably integrated in 24% of regenerated plants, with long-read sequencing supporting precise insertion and inheritance. Extensive specificity profiling was strongest in plants. Authors disclosed patent applications in China and under the PCT; all are employees of Qi Biodesign, and the corresponding author is its founder.<\/p>\n

Deep Analysis<\/h4>\n

Engineering the DNA substrate can complement protein evolution while avoiding some activity-specificity tradeoffs caused by mutations at the integrase DNA-binding interface. The practical innovation is modular co-optimization of enzyme and recognition site, not proof that one attachment sequence will generalize across cell types, loci and cargoes. Therapeutic insertion remains a two-stage delivery problem: prime-editing efficiency sets the landing-pad ceiling, and donor DNA and integrase then must reach the same cell. Large donor exposure, innate sensing, byproducts, chromosomal rearrangements and off-target integration require direct measurement in primary cells and animals. The CD19-CAR and OTC examples connect the platform to cell therapy and metabolic liver disease, but they are payload demonstrations only; functional CAR expression, cytotoxicity, T-cell fitness, hepatic rescue, clonal behavior and durable in-vivo activity were not tested.<\/p>\n

Company and Product Background<\/h4>\n

Qi Biodesign is a Beijing gene-editing company. The study’s authors are company employees, and patent applications cover reported results. Peer review and open methods raise confidence in the measurements but do not remove sponsor-related translation bias. Bxb1 is a large serine integrase that recombines attB and attP sites without relying on double-strand-break repair. PASSIGE-like systems first install one attachment site using prime editing, then integrate a donor carrying the matching site. Large precise insertion could support CAR cassettes, enzyme replacement and synthetic circuits. Clinical development must coordinate editor, guide, integrase and donor delivery while controlling immune sensing, random integration, chromosomal rearrangement and long-term clonal selection.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Key Finding<\/td>\nattB(V111) integration: 51.9% (HEK293T), 35.6% (rice protoplasts)<\/td>\n<\/tr>\n
Therapeutic Payloads<\/td>\n31% CD19-CAR insertion; 25% OTC cassette insertion (HEK293T cells)<\/td>\n<\/tr>\n
Cell Types Tested<\/td>\nHEK293T (human, immortalized), rice protoplasts\/plants; no primary human cells<\/td>\n<\/tr>\n
Plant Validation<\/td>\n5.8 kb cassette stably integrated in 24% of regenerated rice plants<\/td>\n<\/tr>\n
Signal Type<\/td>\nPeer-reviewed platform method, cell-line\/plant stage only<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Engineering the DNA attachment site alongside the integrase protein is an underused lever that produced reproducible, quantitative gains in therapeutic-sized cargo insertion (CD19-CAR, OTC cassette) across two very different biological systems, human cells and plants.<\/p>\n

Bear case:<\/strong> All human data come from an immortalized cell line (HEK293T) rather than primary T cells, hepatocytes or HSPCs, leaving the dominant therapeutic bottlenecks, landing-pad installation, delivery and genotoxicity, entirely untested in clinically relevant contexts.<\/p>\n

InSilens Take<\/h4>\n

This is a 4\/5 uncertain technology signal. The DNA-centric design strategy produced reproducible, quantitative integration gains and therapeutic-sized insertions. It does not yet solve delivery, primary-cell fitness or genotoxicity, so treatment readiness would be premature.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Uncertain · Confidence:<\/strong> High on facts, Low-moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

Qi Biodesign researchers rationally engineered Bxb1 attachment-site DNA rather than only the integrase protein, identifying attB(V111) and related variants that increased large-cargo integration in human cells and plants. Combining engineered DNA and protein produced…<\/p>\n","protected":false},"author":1,"featured_media":2912,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[569,568],"class_list":["post-2907","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-bxb1-integrase","tag-qi-biodesign"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2907"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2907\/revisions"}],"predecessor-version":[{"id":2929,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2907\/revisions\/2929"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2912"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}